TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05649592

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Hydrolipid Separation Imaging
Description: MRHS was used to measure different muscle percent fat of core muscles. MRHS, also called Dixon imaging, mainly used the different resonant frequency between the hydrogen nuclei in water and in fat to perform the data acquisition at different echo times (TE). The Dixon sequence basically acquires two images, one image with water and fat signals in-phase and the other with water and fat signals out-of-phase: the sum and subtraction of the two images allow the production of a water-only image and a fat-only image. Scanning equipment: 3.0T superconducting Siemens Skyra Scanner.~Scanning parameters: TR5.36ms, TE1.24ms, Flip Angle 9°, number of layers was 44-60, thickness of layer was 5.0 mm, layer interval 1.0mm, FOV50cm×50cm, the scanning time was 12s×5.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Hydrolipid Separation Imaging
Description: MRHS was used to measure different muscle percent fat of core muscles. MRHS, also called Dixon imaging, mainly used the different resonant frequency between the hydrogen nuclei in water and in fat to perform the data acquisition at different echo times (TE). The Dixon sequence basically acquires two images, one image with water and fat signals in-phase and the other with water and fat signals out-of-phase: the sum and subtraction of the two images allow the production of a water-only image and a fat-only image. Scanning equipment: 3.0T superconducting Siemens Skyra Scanner.~Scanning parameters: TR5.36ms, TE1.24ms, Flip Angle 9°, number of layers was 44-60, thickness of layer was 5.0 mm, layer interval 1.0mm, FOV50cm×50cm, the scanning time was 12s×5.
Study: NCT04554888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin Topical
Description: Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papain
Description: Papain will be applied by 1 SPT prick thought the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Histamine will be applied by 1 SPT prick thought the skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
Study: NCT06551883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different bowel preparation regime
Description: Patients in Group B receive the 3L of PEG in a single dose

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: traditional bowel preparation regime
Description: Patients in Group A receive the 3L of PEG in a split dose
Study: NCT05907239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Extracorporeal Shockwave Therapy
Description: We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 1.5cm in depth, frequency of 8Hz and intensity of 0.048mJ/mm² as long as it is tolerable to the patient (it can be reduced to a tolerable intensity of at least 0.018mJ/mm²) starting with a density of energy flow between 0.12 to 0.15 mJ/mm2, starting from an adaptation dose of 0.10 mJ/mm2 in the first 500 impulses. The non-stationary technique will be used, slowly moving the applicator. Shockwave therapy will be weekly, totaling five consecutive weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Focused Extracorporeal Shockwave Therapy
Description: We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 0cm depth, frequency of 8Hz and intensity of 0.048mJ/mm² with a fake gel pad applicator.
Study: NCT05341830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery housing
Description: Recovery housing provides housing and other services to individuals who are recovering from substance-use disorders. They provide a substance-free living environment, as well as services to assist residents with life in recovery. These services include connections to employment and educational opportunities, help obtaining documentation such as a driver's license, connection to mutual aid, and assistance building life skills.
Study: NCT06387524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McConnell Taping
Description: Begin with the patient in supine lying with the knee slightly bent. The knee should be completely relaxed and a foam roller or rolled up towel under the knee. Start the tape in line with the middle of the knee cap at the outer aspect of the knee. Using your thumb on top of the sports tape, gently push the patella towards the inner aspect of the knee whilst simultaneously using your fingers to pull the skin at the inner aspect of the knee towards the patella. Finish this taping technique at the inner aspect of the knee ensuring you have created some wrinkling of the skin at the inner aspect of the knee.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECCENTRIC EXERCISES:
Description: Performed for 6 weeks, in 3 sets of 10-12 repetitions each day. Detailed protocol is as under:~Warm up phase (5 minutes) It will comprise of following components 5 minutes warm up exercise protocol: Marching in place while swinging your arm, rotating toe touching, walking jacks, leg swings, arm circles, shoulder shrugs Eccentric exercises: Each of the following exercise will be performed for 30 seconds, repetitions and hold time will increase with increasing weeks according to patient's stamina.~Straight leg raise, side lying hip abduction, single leg bridging, supported double leg squatting, hip hikes,supported single leg squatting Following is the detailed description of Cool down phase: Hip stretch, cat cow stretch, oblique stretch, lower back stretch, calf stretch, cross body shoulder stretch
Study: NCT05671536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interview
Description: Intervention arm will receive motivational interview by the researcher, once a month for 4 times at least 20 minutes. The researcher received education about motivational interview.
Study: NCT06522971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensiy interval training
Description: All participants undergo physical capacity tests before the onset of NAC and after the last course of NAC but before the breast cancer surgery. A treadmill protocol consisting of twenty-one 1-minute stages, with speed and/or grade increments at each stage, is used to obtain VO2 peak (the highest amount of oxygen consumed at peak exercise) data. The HIIT intervention consists of 2 to 3 exercise sessions per week for 6 months. The HIIT session starts with a 6-minute warm-up period at about 65-70% of maximal heart rate (HRmax) followed by 4 X 4-min high-intensity intervals (85%-95% of HRmax) combined with 3 min period of active recovery (55-70% of HRmax).
Study: NCT06464861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-NK/T
Description: Cord blood derived CD19 CARNK sequential Treatment with 7x19 CAR-T
Study: NCT05364762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study: NCT05565768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-457
Description: HZN-457 will be given in one subcutaneous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in one subcutaneous administration
Study: NCT06201351

Intervention type: DEVICE
Intervention: adaptive radiotherapy
Description: MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
Study: NCT05760534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: 0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
Study: NCT06365840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-001
Description: All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.
Study: NCT05133102

Intervention type: OTHER
Intervention: Sample collection
Description: Collection of saliva sample

Intervention type: OTHER
Intervention: Sample collection
Description: Collection of saliva sample
Study: NCT05992051

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: Exercise therapy is considered as the integral component of interventions for chronic non-specific neck pain. It includes different type resistance training, range of motion exercises and stretching exercises to improve neck condition and release symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Exercise therapy is considered as the integral component of interventions for chronic non-specific neck pain. It includes different type resistance training, range of motion exercises and stretching exercises to improve neck condition and release symptoms.
Study: NCT05521542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter
Description: SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter is a Drug-Coated Balloon to treat de novo lesions in patients with symptomatic stable angina, unstable angina, or NSTEMI
Study: NCT05314621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine hydrochloride ophthalmic solution 0.7%)
Description: Pataday® Once Daily Relief Extra Strength (eyedrop)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Flonase® Allergy Relief (nasal spray)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tears Naturale
Description: Tears Naturale® II (eye drop)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline nasal spray
Description: Saline nasal spray (nasal spray)
Study: NCT05629910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2Matic
Description: During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
Study: NCT05936827

Intervention type: DIAGNOSTIC_TEST
Intervention: Ergometry
Description: Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion.~The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine.~ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams \& Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Ergospirometry
Description: VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion.~Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)
Study: NCT05262842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001+IMP4297
Description: Phase I: Dose Escalation The primary endpoints are the safety and tolerability of the combination, including the incidence and nature of DLTs and the determination of the MTD and RP2D. A 3 + 3 dose-escalation (60mg,80mg,100mg)design will be used. Patient in each dose level will be treated with toripalimab 240mg in combination with senaparib.~Phase Ib: Dose Expansion This part will commence after the RP2D is determined and will further evaluate the safety and anti-tumor activity of toripalimab and senaparib in patients with specific types of advanced solid tumors. Patients will be enrolled concurrently into 5 exploratory cohorts with approximately 20 patients each cohort.
Study: NCT05789823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy combined with ischemic post-conditioning
Description: Ischemic post-conditioning will be applied after successful recanalization of the culprit artery achieve by thrombectomy. Ischemic post-conditioning consists of briefly repeated 4 cycles × 5 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Mechanical thrombectomy alone
Description: Successful recanalization was achieved by mechanical thrombectomy without subsequent ischemic post-conditioning.
Study: NCT06465537

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD113vVLP
Description: CRISPR/Cas9 gene editing technology, called BD113vVLP (also BD113 virus-like particle) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down the mutated MYOC gene. The BD113vVLP is administrated by intracamerally injecton (sigle-dose: 4ug/p24) for each target interventional eye.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD113vVLP
Description: CRISPR/Cas9 gene editing technology, called BD113vVLP (also BD113 virus-like particle) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down the mutated MYOC gene. The BD113vVLP is administrated by intracamerally injecton (sigle-dose: 4ug/p24) for each target interventional eye.
Study: NCT05008003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care treatment as per the hospital guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care treatment as per the hospital guidelines

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: A daily dose of 5000 IU vitamin D3 for 7 days.
Study: NCT05168280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: The 0.9% saline is administered with the same volume at the same speed as the other group.
Study: NCT06063057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
Description: Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
Description: Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
Description: Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enterovirus type EV71 vaccine (Vero cell), Inactivated
Description: Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)
Study: NCT05524337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: white noise
Description: Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic touch
Description: In the group where therapeutic touch will be applied, the heel blood collection procedure and the study will be explained to the family, and after the consent is obtained, the therapeutic touch will be applied to the baby 5 minutes before, during and after the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: white noise and therapeutic touch
Description: the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time.
Study: NCT06505798

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Catheter Ablation
Description: Participants randomised to the catheter ablation arm will undergo Pulmonary Vein Isolation (PVI) which is the essential ablation intervention. The technique used will be at the discretion of the treating physician but may include Cryoballoon (Medtronic/Boston Scientific), Radiofrequency: CARTO (Biosense), pulsed field radiofrequency ablation, or Precision (Abbott Medical) electro-anatomical mapping systems. Additional ablation lesions may be delivered as preferred by the operator and will be documented. Electro-anatomical voltage maps will be collected (in SR/AF) and stored for later analysis.
Study: NCT05092152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: 2 mg per kilogram of body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 1.5 mg per kilogram of body weight
Study: NCT05054504

Intervention type: DEVICE
Group type: OTHER
Intervention: Butterfly iQ
Description: The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.
Study: NCT05033756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Tablet [Lynparza]
Description: All patients will receive olaparib treatment as an addition to pembrolizumab. The dose of olaparib used in this study is 300 mg twice daily (total daily dose of 600 mg) which is the currently approved dose.
Study: NCT06430086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut consumption
Description: Participants will add one serving (1 oz) of walnuts at their self-defined breakfast, lunch, and dinner for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut consumption
Description: Participants will add one serving (1 oz) of walnuts at their self-defined breakfast, lunch, and dinner for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCHS consumption
Description: Participants will add one HCHS food (one PopTarts® pastry) to each of their 3 main meals of the day for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.~An energy-matched high-carbohydrate, high-sugar (HCHS) alternative, representative of a common US snack food, on sleep quality in adults with habitually poor sleep quality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCHS consumption
Description: Participants will add one HCHS food (one PopTarts® pastry) to each of their 3 main meals of the day for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.~An energy-matched high-carbohydrate, high-sugar (HCHS) alternative, representative of a common US snack food, on sleep quality in adults with habitually poor sleep quality.
Study: NCT05904210

Intervention type: DRUG
Intervention: SEVENFACT®
Description: Coagulation Factor VIIa (Recombinant)
Study: NCT04704856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise
Description: Supervised exercise during first 6 weeks of neoadjuvant chemotherapy.
Study: NCT06755346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis plant (THC 20mg)
Description: Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis (0%/ THC / 0% CBD)
Description: THC (0%) / CBD (0%) - Placebo marijuana
Study: NCT05167903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Diet
Description: All praticipants in ND will perform supervised and monitored RT three time per week for the 10 weeks of intervention. The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: All participants in TRE will perform supervised and monitored RT three time per week for the 10 weeks of intervention. Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm, and to avoid consumption of food or caloric drinks during the fasting period (8 h eating window with 16 h of fasting).